INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...

Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently granted priority review to the supplemental Biologics License Application for Emgality ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Emgality, a once-monthly, self-administered, subcutaneous injection, for the preventive ...

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...

Eli Lilly may not be first to the market with its next-gen migraine drug Emgality, but with an approval Thursday, the drugmaker still believes it can be the “treatment of choice” for migraine ...

It happened! After yearning for the new “miracle” migraine drug, I was finally approved for monthly injections. So, that’s the good news. The bad news is that ...